| scholarly article | Q13442814 |
| P50 | author | George M. Church | Q3298995 |
| Norbert Perrimon | Q38523404 | ||
| Benjamin E Housden | Q56947122 | ||
| Emma J K Kowal | Q57201427 | ||
| Benjamin W Pruitt | Q57513718 | ||
| Ben S Ewen-Campen | Q30506235 | ||
| P2093 | author name string | James J Collins | |
| Raj Chari | |||
| Dmitry Ter-Ovanesyan | |||
| Alejandro Chavez | |||
| Joanna Buchthal | |||
| Marcelle Tuttle | |||
| Ryan J Cecchi | |||
| Sabina J Haque | |||
| P2860 | cites work | Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals | Q22122053 |
| RNA-guided human genome engineering via Cas9 | Q24598394 | ||
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes | Q24625361 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation | Q26775746 | ||
| Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy. | Q38525774 | ||
| Synergistic and tunable human gene activation by combinations of synthetic transcription factors | Q43080289 | ||
| The New State of the Art: Cas9 for Gene Activation and Repression | Q26787037 | ||
| Linear models and empirical bayes methods for assessing differential expression in microarray experiments | Q27860758 | ||
| Enzymatic assembly of DNA molecules up to several hundred kilobases | Q28241142 | ||
| Development and applications of CRISPR-Cas9 for genome engineering | Q28241526 | ||
| RNA-guided gene activation by CRISPR-Cas9-based transcription factors | Q28295458 | ||
| The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA | Q28297640 | ||
| The Mediator complex and transcription regulation | Q28299679 | ||
| RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome | Q29547458 | ||
| CRISPR-Cas systems for editing, regulating and targeting genomes | Q29615781 | ||
| CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering | Q29615783 | ||
| CRISPR RNA-guided activation of endogenous human genes | Q29617072 | ||
| A protein-tagging system for signal amplification in gene expression and fluorescence imaging | Q30604320 | ||
| voom: Precision weights unlock linear model analysis tools for RNA-seq read counts | Q33741687 | ||
| Optimized CRISPR/Cas tools for efficient germline and somatic genome engineering in Drosophila | Q33971898 | ||
| Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex | Q34042665 | ||
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. | Q34043681 | ||
| Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells | Q34093413 | ||
| Enzymatic assembly of overlapping DNA fragments | Q34186536 | ||
| Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. | Q34436638 | ||
| Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation | Q34443093 | ||
| Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach | Q34484605 | ||
| The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli | Q34631401 | ||
| A CRISPR/Cas9-based system for reprogramming cell lineage specification. | Q34684505 | ||
| Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds | Q34979506 | ||
| Highly efficient Cas9-mediated transcriptional programming | Q35372727 | ||
| In Vivo Transcriptional Activation Using CRISPR/Cas9 in Drosophila | Q36132221 | ||
| Robust, synergistic regulation of human gene expression using TALE activators | Q36644568 | ||
| Editing the epigenome: technologies for programmable transcription and epigenetic modulation | Q37042113 | ||
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system | Q37214501 | ||
| High local concentration: a fundamental strategy of life | Q37626167 | ||
| Transcription factors: from enhancer binding to developmental control | Q38032407 | ||
| Synthetic fusion protein design and applications | Q38275670 | ||
| P433 | issue | 7 | |
| P921 | main subject | Cas9 | Q16965677 |
| P304 | page(s) | 563-567 | |
| P577 | publication date | 2016-05-23 | |
| P1433 | published in | Nature Methods | Q680640 |
| P1476 | title | Comparison of Cas9 activators in multiple species | |
| P478 | volume | 13 |
| Q67087244 | A CRISPR Activation Screen Identifies Genes That Protect against Zika Virus Infection |
| Q47659785 | A CRISPR reimagining: New twists and turns of CRISPR beyond the genome-engineering revolution. |
| Q58741933 | A CRISPR/Cas9 Toolkit for Conditionally Manipulating Gene Expression in the Prothoracic Gland as a Test Case for Polytene Tissues |
| Q64120389 | A Neuron-Optimized CRISPR/dCas9 Activation System for Robust and Specific Gene Regulation |
| Q58609968 | A Regeneration Toolkit |
| Q98895548 | A gene therapy for inherited blindness using dCas9-VPR-mediated transcriptional activation |
| Q47329461 | A potent Cas9-derived gene activator for plant and mammalian cells |
| Q92578973 | A split CRISPR-Cpf1 platform for inducible genome editing and gene activation |
| Q92453382 | A tunable orthogonal coiled-coil interaction toolbox for engineering mammalian cells |
| Q27468938 | Advances and perspectives in the application of CRISPR/Cas9 in insects |
| Q47715721 | Advancing biotechnology with CRISPR/Cas9: recent applications and patent landscape |
| Q47281660 | Am I ready for CRISPR? A user's guide to genetic screens |
| Q52431745 | An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance. |
| Q38696368 | An all-in-one UniSam vector system for efficient gene activation |
| Q64067683 | An artificial triazole backbone linkage provides a split-and-click strategy to bioactive chemically modified CRISPR sgRNA |
| Q101564050 | An endoribonuclease-based feedforward controller for decoupling resource-limited genetic modules in mammalian cells |
| Q95595094 | An enhanced CRISPR repressor for targeted mammalian gene regulation |
| Q92606669 | Antagonistic and synergistic epigenetic modulation using orthologous CRISPR/dCas9-based modular system |
| Q38947491 | Applications of CRISPR Genome Engineering in Cell Biology |
| Q42377848 | Bidirectional manipulation of gene expression in adipocytes using CRISPRa and siRNA. |
| Q48376848 | CRISPR Approaches to Small Molecule Target Identification |
| Q87985442 | CRISPR Editing in Biological and Biomedical Investigation |
| Q39014648 | CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes |
| Q48297340 | CRISPR-Cas type II-based Synthetic Biology applications in eukaryotic cells. |
| Q90169796 | CRISPR-based Activation of Endogenous Neurotrophic Genes in Adipose Stem Cell Sheets to Stimulate Peripheral Nerve Regeneration |
| Q101356304 | CRISPR-based metabolic pathway engineering |
| Q92731752 | CRISPR-induced double-strand breaks trigger recombination between homologous chromosome arms |
| Q62937894 | CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. |
| Q59352251 | CRISPR-typing PCR (ctPCR), a new Cas9-based DNA detection method |
| Q92403299 | CRISPR/Cas9 Genome Editing Introduction and Optimization in the Non-model Insect Pyrrhocoris apterus |
| Q59351134 | CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges |
| Q47329392 | CRISPR/Cas9 library screening for drug target discovery |
| Q47594679 | CRISPR/Cas9-Based Engineering of the Epigenome |
| Q89873570 | CRISPR/Cas9-mediated genome editing: From basic research to translational medicine |
| Q93170704 | CRISPRai for simultaneous gene activation and inhibition to promote stem cell chondrogenesis and calvarial bone regeneration |
| Q46190066 | CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine |
| Q91272447 | Cancer therapy with a CRISPR-assisted telomerase-activating gene expression system |
| Q98771604 | Cell Reprogramming With CRISPR/Cas9 Based Transcriptional Regulation Systems |
| Q93081159 | Cell and Gene Therapies for Mucopolysaccharidoses: Base Editing and Therapeutic Delivery to the CNS |
| Q47746875 | Chemical Control of a CRISPR-Cas9 Acetyltransferase. |
| Q99605551 | Clearing of Foreign Episomal DNA from Human Cells by CRISPRa-Mediated Activation of Cytidine Deaminases |
| Q92285878 | Coactivation of Endogenous Wnt10b and Foxc2 by CRISPR Activation Enhances BMSC Osteogenesis and Promotes Calvarial Bone Regeneration |
| Q46571818 | Combinatorial genetics in liver repopulation and carcinogenesis with a novel in vivo CRISPR activation platform. |
| Q36142402 | Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. |
| Q33704483 | Complex transcriptional modulation with orthogonal and inducible dCas9 regulators. |
| Q58755636 | Comprehensive off-target analysis of dCas9-SAM-mediated HIV reactivation via long noncoding RNA and mRNA profiling |
| Q39051110 | Cornerstones of CRISPR-Cas in drug discovery and therapy |
| Q64375251 | Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing |
| Q48230762 | Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage. |
| Q91692625 | Dead Cas Systems: Types, Principles, and Applications |
| Q55097609 | Design principles for nuclease-deficient CRISPR-based transcriptional regulators. |
| Q36256836 | Diversity and evolution of class 2 CRISPR-Cas systems |
| Q91236224 | Dose-dependent activation of gene expression is achieved using CRISPR and small molecules that recruit endogenous chromatin machinery |
| Q28075883 | Editing the Neuronal Genome: a CRISPR View of Chromatin Regulation in Neuronal Development, Function, and Plasticity |
| Q90835425 | Effective CRISPRa-mediated control of gene expression in bacteria must overcome strict target site requirements |
| Q41664346 | Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors. |
| Q47142589 | Engineering cell sensing and responses using a GPCR-coupled CRISPR-Cas system |
| Q99233898 | Engineering multiple species-like genetic incompatibilities in insects |
| Q42376153 | Engineering species-like barriers to sexual reproduction. |
| Q64389324 | Enhanced Bacterial Immunity and Mammalian Genome Editing via RNA-Polymerase-Mediated Dislodging of Cas9 from Double-Strand DNA Breaks |
| Q89550961 | Epigenetic Control of a Local Chromatin Landscape |
| Q41327318 | Evaluating Synthetic Activation and Repression of Neuropsychiatric-Related Genes in hiPSC-Derived NPCs, Neurons, and Astrocytes |
| Q64098881 | Expanding the repertoire of glucocorticoid receptor target genes by engineering genomic response elements |
| Q47356373 | From Reductionism to Holism: Toward a More Complete View of Development Through Genome Engineering. |
| Q39014872 | From profiles to function in epigenomics. |
| Q36306820 | Functional interrogation of non-coding DNA through CRISPR genome editing |
| Q64054412 | Gene activation by a CRISPR-assisted enhancer |
| Q91619703 | Gene activation by dCas9-CBP and the SAM system differ in target preference |
| Q90618258 | Gene editing and CRISPR in the clinic: current and future perspectives |
| Q64270202 | Generate TALE/TALEN as Easily and Rapidly as Generating CRISPR |
| Q90612123 | Generating and working with Drosophila cell cultures: Current challenges and opportunities |
| Q33777855 | Genetic and epigenetic control of gene expression by CRISPR-Cas systems |
| Q89881392 | Genetically Engineering the Nervous System with CRISPR-Cas |
| Q92276489 | Genome Editing as a Treatment for the Most Prevalent Causative Genes of Autosomal Dominant Retinitis Pigmentosa |
| Q64068207 | Genome-Scale CRISPRa Screen Identifies Novel Factors for Cellular Reprogramming |
| Q34553929 | Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening |
| Q47594697 | High-Throughput Approaches to Pinpoint Function within the Noncoding Genome |
| Q90044573 | High-Throughput Screens of PAM-Flexible Cas9 Variants for Gene Knockout and Transcriptional Modulation |
| Q55509998 | Human pluripotent reprogramming with CRISPR activators. |
| Q91869843 | Identification of on-target mutagenesis during correction of a beta-thalassemia splice mutation in iPS cells with optimised CRISPR/Cas9-double nickase reveals potential safety concerns |
| Q45873745 | Immunity to CRISPR Cas9 and Cas12a therapeutics |
| Q47863605 | In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice. |
| Q46200383 | Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors. |
| Q92932156 | Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing |
| Q46727259 | In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation. |
| Q97905534 | Isolating live cell clones from barcoded populations using CRISPRa-inducible reporters |
| Q36271299 | Iterative optimization of xylose catabolism in Saccharomyces cerevisiae using combinatorial expression tuning |
| Q89766592 | Large-Scale Transgenic Drosophila Resource Collections for Loss- and Gain-of-Function Studies |
| Q93095848 | Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models |
| Q37550614 | Loss-of-function genetic tools for animal models: cross-species and cross-platform differences |
| Q37576628 | Mammalian synthetic biology for studying the cell. |
| Q55261643 | Mouse medulloblastoma driven by CRISPR activation of cellular Myc. |
| Q47252909 | Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing |
| Q90170474 | Multiplexed CRISPR technologies for gene editing and transcriptional regulation |
| Q50939969 | Multiplexed Transcriptional Activation or Repression in Plants Using CRISPR-dCas9-Based Systems. |
| Q92735568 | Multiplexed and tunable transcriptional activation by promoter insertion using nuclease-assisted vector integration |
| Q90462210 | Neuron-specific signatures in the chromosomal connectome associated with schizophrenia risk |
| Q52431639 | Next-generation CRISPR/Cas9 transcriptional activation in Drosophila using flySAM. |
| Q55261613 | Novel internal regulators and candidate miRNAs within miR-379/miR-656 miRNA cluster can alter cellular phenotype of human glioblastoma. |
| Q60300359 | Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities |
| Q48693085 | Optimized strategy for in vivo Cas9-activation in Drosophila |
| Q97681129 | Photoactivatable oncolytic adenovirus for optogenetic cancer therapy |
| Q47593181 | Plant Gene Regulation Using Multiplex CRISPR-dCas9 Artificial Transcription Factors |
| Q92352527 | Porcine antiviral activity is increased by CRISPRa-SAM system |
| Q97544128 | Programmable CRISPR-Cas transcriptional activation in bacteria |
| Q41701373 | Rapid and reversible epigenome editing by endogenous chromatin regulators |
| Q37682943 | Rational design of inducible CRISPR guide RNAs for de novo assembly of transcriptional programs |
| Q58769194 | Rationally-engineered reproductive barriers using CRISPR & CRISPRa: an evaluation of the synthetic species concept in Drosophila melanogaster |
| Q92709516 | Regulation of gene expression by altered promoter methylation using a CRISPR/Cas9-mediated epigenetic editing system |
| Q39390088 | Repurposing CRISPR System for Transcriptional Activation |
| Q96609271 | Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells |
| Q90323842 | Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells |
| Q64231481 | Split-TALE: A TALE-Based Two-Component System for Synthetic Biology Applications in Planta |
| Q30356570 | Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells. |
| Q98945200 | Synthetic immunomodulation with a CRISPR super-repressor in vivo |
| Q47356354 | Target Discovery for Precision Medicine Using High-Throughput Genome Engineering |
| Q93010776 | Targeted Transcriptional Activation in Plants Using a Potent Dead Cas9-Derived Synthetic Gene Activator |
| Q91909950 | Targeted regulation of fibroblast state by CRISPR-mediated CEBPA expression |
| Q55233775 | The CRISPR tool kit for genome editing and beyond. |
| Q46453776 | The emerging role of systems biology for engineering protein production in CHO cells |
| Q92421336 | The giant titin: how to evaluate its role in cardiomyopathies |
| Q90299491 | Three-Component Repurposed Technology for Enhanced Expression: Highly Accumulable Transcriptional Activators via Branched Tag Arrays |
| Q47215199 | Transcription control engineering and applications in synthetic biology. |
| Q38877182 | Transcriptional regulation with CRISPR-Cas9: principles, advances, and applications |
| Q90441183 | Validation of a Miniaturized Permeability Assay Compatible with CRISPR-Mediated Genome-Wide Screen |
| Q38756988 | What rheumatologists need to know about CRISPR/Cas9. |
| Q90677984 | dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice |
Search more.